Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Gynaecol Obstet ; 24(4): 291-6, 1986 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-2878838

RESUMEN

Oral glucose tolerance test and determination of insulin, cholesterol, triglycerides, total bilirubin, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase and cortisol in blood were performed on 57 Thai women who had used depot-medroxyprogesterone acetate (DMPA) for 5 years or more and 24 healthy non-DMPA users. Plasma insulin, alkaline phosphatase and morning cortisol levels were significantly higher in the DMPA users than in the non-users. There were no significant differences for other laboratory tests. The findings suggest some effects of DMPA on carbohydrate metabolism and liver function in long-term users.


Asunto(s)
Medroxiprogesterona/análogos & derivados , Adulto , Fosfatasa Alcalina/sangre , Anticonceptivos Sintéticos Orales/metabolismo , Estudios Transversales , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Hidrocortisona/sangre , Insulina/sangre , Medroxiprogesterona/sangre , Medroxiprogesterona/metabolismo , Acetato de Medroxiprogesterona , Persona de Mediana Edad , Embarazo , Tailandia , Factores de Tiempo
2.
Contraception ; 22(4): 397-408, 1980 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7449388

RESUMEN

PIP: Norethisterone oenanthate (NET-OEN), an injectable contraceptive preparation containing 200 mg of steroid in 1 ml oily solution, was administered to 126 healthy Thai women of proven fertility (age, 18 to 35) at 8-week and then 12-week intervals. Vaginal bleeding, weight, blood pressure and menstrual bleeding were recorded during each visit, as were complaints and adverse effect. The 12-month continuation rate was 63/100 women-years with 5 accidental pregnancies. There were 2 pregnancies during the 2nd injection interval and 3 other pregnancies during the 3rd, 4th, and 5th injection intervals. Most frequent complaints were spotting, 32.4% and amenorrhea, 26.2%. 3.8% experienced heavy bleeding while 11.2% reported vertigo, nausea and vomiting. There were 11/100 women-years of amenorrhea, and 25/100 women-years of heavy bleeding. A statistically significant increase in the serum glucose tolerance test (p 0.05) was noted after 12 months of use, but the increase was within normal limits. The significant transient decrease in total cholesterol and triglyceride levels observed at the 3rd month of study returned to normal after 6 months.^ieng


Asunto(s)
Noretindrona/farmacología , Adolescente , Adulto , Presión Sanguínea/efectos de los fármacos , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Noretindrona/efectos adversos , Noretindrona/metabolismo , Embarazo , Tailandia , Hemorragia Uterina/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA